Clinical Trial Phases in Oncology: What FRCR Candidates Need to Know

As a clinical oncologist, you'll encounter clinical trial data daily—interpreting results, discussing treatment options with patients, and potentially conducting research yourself. The Medical Statistics module of FRCR Part 1 tests your understanding of trial design, including the different phases of drug development.

Clinical trials are conducted in phases, each with specific objectives. A drug must successfully pass through Phases I, II, and III before regulatory approval (by bodies like the FDA or MHRA), after which Phase IV post-marketing surveillance continues.

Phase 0: Exploratory (Microdosing) Studies

Phase 0 trials are optional exploratory studies introduced by the FDA in 2006 to accelerate drug development.

Purpose

• Confirm that a drug behaves in humans as predicted from preclinical (laboratory and animal) studies
• Obtain early pharmacokinetic (PK) data—how the body processes the drug

Key Features

• Participants: Very small numbers (typically <15)
• Dose: Subtherapeutic microdoses (1/100th of the estimated therapeutic dose)
• Duration: Short exposure period
• Outcome: No expectation of therapeutic benefit

Note: Phase 0 trials help make "go/no-go" decisions early, potentially saving time and resources. However, they're not universally used and are not a regulatory requirement.

Phase I: First-in-Human / Safety Studies

Phase I trials are the first time a new drug is tested in humans. In oncology, these typically enroll patients with advanced cancer who have exhausted standard treatment options.

Primary Objectives

• Establish safety and tolerability
• Determine the Maximum Tolerated Dose (MTD)
• Identify Dose-Limiting Toxicities (DLTs)
• Study pharmacokinetics and pharmacodynamics

Key Features

• Participants: Small numbers (typically 20-80 patients)
• Design: Dose escalation—patients receive increasing doses in cohorts
• 3+3 design: The traditional approach where 3 patients receive a dose level; if no DLT occurs, the next 3 receive a higher dose
• Rolling Six design: Allows more continuous enrollment, reducing trial duration
• Outcome: Recommend a dose for Phase II (RP2D = Recommended Phase 2 Dose)

Oncology difference: Unlike most Phase I trials (which use healthy volunteers), oncology Phase I trials enroll patients with advanced cancer. This is because the drugs being tested are often cytotoxic or have significant risks that wouldn't be ethical to expose healthy volunteers to.

Phase II: Efficacy Signal Studies

Phase II trials assess whether the drug shows signs of working ("proof of concept") while continuing to monitor safety.

Primary Objectives

• Evaluate preliminary efficacy in a specific cancer type
• Further assess safety profile
• Refine dosing schedule

Key Features

• Participants: Larger numbers (typically 50-300 patients with a specific cancer type)
• Design: May be single-arm (all patients receive experimental drug) or randomised
• Phase IIa: Exploratory, focused on dosing and early efficacy signals
• Phase IIb: More rigorous, may compare to standard treatment
• Endpoints: Often use surrogate endpoints like Response Rate (RR) or Progression-Free Survival (PFS)

Success rate: Only about 30-40% of cancer drugs that enter Phase II proceed to Phase III.

Phase III: Confirmatory / Pivotal Trials

Phase III trials provide the definitive evidence needed for regulatory approval. They compare the new treatment against the current standard of care.

Primary Objectives

• Confirm efficacy compared to standard treatment
• Monitor adverse effects in larger populations
• Provide data for regulatory submission

Key Features

• Participants: Large numbers (typically 300 to several thousand patients)
• Design: Randomised Controlled Trials (RCTs), often double-blinded
• Comparator: Standard of care (or placebo if no standard exists)
• Endpoints: Often Overall Survival (OS) or PFS; quality of life measures
• Multi-centre: Usually conducted across multiple sites, often internationally

Regulatory outcome: Successful Phase III trials support a New Drug Application (NDA) to regulatory bodies. If approved, the drug becomes the new standard of care.

Phase IV: Post-Marketing Surveillance

Phase IV trials occur after a drug has been approved and is available for clinical use.

Primary Objectives

• Monitor long-term safety in larger, more diverse populations
• Detect rare adverse effects not seen in smaller trials
• Assess real-world effectiveness
• Explore use in additional indications

Key Features

• Participants: Can involve thousands of patients
• Design: Often observational or registry-based
• Duration: May continue for years
• Setting: Routine clinical practice

Safety signals: Phase IV studies may identify safety concerns that lead to label changes, restricted indications, or even drug withdrawal.

Summary Table: Clinical Trial Phases

Phase	Primary Focus	Typical Size	Key Outcome
0	Pharmacokinetics	<15	PK data for go/no-go decision
I	Safety, MTD	20-80	Recommended Phase II Dose
II	Efficacy signal	50-300	Proof of concept
III	Confirmatory efficacy	300-3,000+	Regulatory approval data
IV	Long-term safety	Thousands	Real-world safety and effectiveness

Key Concepts for FRCR Part 1

1. Phase I determines safety and MTD using dose escalation (typically 3+3 design)
2. Oncology Phase I trials use patients (not healthy volunteers)
3. Phase II provides preliminary efficacy evidence (proof of concept)
4. Phase III is the pivotal trial for regulatory approval—usually randomised, controlled, and often blinded
5. Phase IV monitors safety in routine clinical practice after approval
6. Understand surrogate endpoints (PFS, RR) vs. definitive endpoints (OS)

Practice with PassOncology

Our Medical Statistics module includes questions on clinical trial design, phases, endpoints, and statistical interpretation. Master these concepts and approach your exam with confidence.

Access our question bank